Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabidiol (CBD) is a non-psychoactive compound derived from the Cannabis sativa plant. Its use in supporting or treating dermatitis is primarily justified by emerging scientific evidence rather than long-standing traditional use. Several preclinical studies have shown that CBD possesses anti-inflammatory, immunomodulatory, and antipruritic (anti-itch) properties, which are relevant to the pathophysiology of dermatitis. Research suggests that CBD can interact with the endocannabinoid system and other molecular targets in the skin, helping to regulate inflammation and skin barrier function. For example, in vitro studies have demonstrated that CBD can reduce the production of pro-inflammatory cytokines in keratinocytes. Some small-scale human studies and case reports have indicated that topical CBD products may help alleviate symptoms such as itching and inflammation in conditions like atopic dermatitis and psoriasis.

However, the overall evidence base remains limited. Most supporting data come from animal models or laboratory studies rather than large-scale, randomized controlled trials in humans with dermatitis. The available clinical studies tend to have small sample sizes, short durations, and varying formulations of CBD, making it difficult to draw definitive conclusions about efficacy and safety. Therefore, while there is some scientific rationale for using CBD in dermatitis, it is best considered an adjunctive or experimental approach until more robust clinical trials are conducted.

More about Cannabidiol
More about Dermatitis

Other ingredients used for Dermatitis

Other health conditions supported by Cannabidiol

Products containing Cannabidiol